The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
Open accessAbstract
BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population. METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits. RESULTS: Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates. CONCLUSIONS: The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin alone was used to lower blood glucose in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study of type 1 diabetes, while a variety of agents were used in clinical trials of type 2 diabetes, supporting the conclusion that lowering blood glucose itself helps prevent CKD and its progression.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In both T1D or T2D, lower achieved levels of HbA1c < 7% ( < 53 mmol/mol) versus 8% -9% (64 -75 mmol/mol) reduce risk of overall microvascular complications, including nephropathy and retinopathy, and macrovascular complications in some RCTs. 189 -193”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In RCTs, targeting lower HbA1c values using glucose-lowering medications has been proven to reduce risks of microvascular diabetes complications (i.e., kidney disease, retinopathy, neuropathy) and, in some studies, also macrovascular diabetes complications (i.e., cardiovascular events).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (54,55) and type 2 diabetes (1,56,57).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Intensive lowering of blood glucose with the goal of achieving near-normoglycemia has been shown in large, randomized studies to delay the onset and progression of albuminuria and reduce eGFR in people with type 1 diabetes (52,53) and type 2 diabetes (1,(54)(55)(56)(57)(58)(59).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“However, the bene fi ts of more-stringent glycemic control (i.e., lower HbA1c targets) compared with less-stringent glycemic control (i.e., higher HbA1c targets) manifest over many years of treatment. 191,248,249”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“In randomized clinical trials, it has taken a number of years for bene fi ts of intensive glycemic control to manifest as improved clinical outcomes. 190,191,234,245,246,248,256”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationA Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citationA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Flagged first, then by citations
Cited by
Sorted by citations
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
KDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Thomas, M. C., Brownlee, M., Suszták, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P. R., Groop, P., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,335
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M. A., Bonventre, J. V., Coresh, J., Donner, J., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 961
Selby, N. M., & Taal, M. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14007 · Cited by 831
Trends in Prevalence of Chronic Kidney Disease in the United States
Murphy, D. P., McCulloch, C. E., Lin, F., Banerjee, T., Bragg‐Gresham, J. L., Eberhardt, M. S., Morgenstern, H., Pavkov, M. E., Saran, R., Powe, N. R., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0273 · Cited by 639
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Kato, M. V., & Natarajan, R. D. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0135-6 · Cited by 615
Update of pathophysiology and management of diabetic kidney disease
Lin, Y., Chang, Y.-H., Yang, S., Wu, K., & Chu, T. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.007 · Cited by 583
Diabetic Microvascular Disease: An Endocrine Society Scientific Statement
Barrett, E. J., Liu, Z., Khamaisi, M., King, G. L., Klein, R., Klein, R., Hughes, T. M., Craft, S., Freedman, B. I., Bowden, D. W., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01922 · Cited by 537
Type 1 Diabetes Mellitus and Cardiovascular Disease
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 516
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality
Orchard, T. J., Nathan, D. M., Zinman, B., Cleary, P., Brillon, D., Backlund, J.-Y. C., & Lachin, J. M. (2015) · JAMA · doi:10.1001/jama.2014.16107 · Cited by 437
de Ferranti, S. D., de Boer, I. H., Fonseca, V. A., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Diabetes Care · doi:10.2337/dc14-1720 · Cited by 444
Diabetic Nephropathy: An Overview
Sagoo, M. K., & Gnudi, L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9841-8_1 · Cited by 439
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 416
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 398
Markers of and Risk Factors for the Development and Progression of Diabetic Kidney Disease
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.048 · Cited by 392
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Gałecki, A. T., Spino, C., Pop‐Busui, R., Cherney, D. Z. I., Lingvay, I., Parsa, A., Rossing, P. R., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 391
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Trajectories of kidney function in diabetes: a clinicopathological update
Oshima, M., Shimizu, M., Yamanouchi, M., Toyama, T., Hara, A., Furuichi, K., & Wada, T. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00462-y · Cited by 358
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
Diabetic nephropathy—emerging epigenetic mechanisms
Kato, M. V., & Natarajan, R. D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.116 · Cited by 319
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes
Perkovic, V., Heerspink, H. L., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M. E., Hamet, P., Marre, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.401 · Cited by 316
10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 316
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D. M., Johnson, E. L., et al. (2022) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 310
Królewski, A. S., Niewczas, M. A., SKUPIEN, J. K., Gohda, T., Smiles, A. M., Eckfeldt, J. H., Doria, A., & Warram, J. H. (2013) · Diabetes Care · doi:10.2337/dc13-0985 · Cited by 279
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., et al. (2023) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 324
Nathan, D. M., Bayless, M., Cleary, P. A., GENUTH, S. M., Gubitosi‐Klug, R., Lachin, J. M., Lorenzi, G. M., & Zinman, B. (2013) · Diabetes · doi:10.2337/db13-1093 · Cited by 277
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
Molitch, M. E., Adler, A. I., Flyvbjerg, A., Nelson, R. G., So, W.-Y., Wanner, C., Kasiske, B. L., Wheeler, D. C., de Zeeuw, D., & Mogensen, C. E. (2015) · Kidney International · doi:10.1038/ki.2014.128 · Cited by 268
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
de Boer, I. H., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2113 · Cited by 254
Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON
Wong, M. G., Perkovic, V., Chalmers, J., Woodward, M., Li, Q., Cooper, M. E., Hamet, P., Harrap, S., Heller, S., MacMahon, S., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2322 · Cited by 240
Jiang, W., Wang, J., Shen, X., Lu, W., Wang, Y., Li, W., Gao, Z., Xu, J., Li, X., Liu, R., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1897 · Cited by 234
Diabetic nephropathy: Is there a role for oxidative stress?
Sagoo, M. K., & Gnudi, L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.040 · Cited by 237
Drawz, P. E., & Rahman, M. U. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201506020 · Cited by 242
Protective Factors and the Pathogenesis of Complications in Diabetes
Yu, M. G., Gordin, D., Fu, J., Park, K., Li, Q., & King, G. L. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad030 · Cited by 252
Testa, R., Bonfigli, A. R., Prattichizzo, F., Sala, L. L., Nigris, V. D., & Ceriello, A. (2017) · Nutrients · doi:10.3390/nu9050437 · Cited by 239
Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes
Królewski, A. S. (2015) · Diabetes Care · doi:10.2337/dc15-0184 · Cited by 220
Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes
Królewski, A. S., SKUPIEN, J. K., Rossing, P. R., & Warram, J. H. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.046 · Cited by 220
Clinical predictive factors in diabetic kidney disease progression
Radcliffe, N. J., Seah, J., Clarke, M. V., MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12533 · Cited by 214
Cardiovascular disease in chronic kidney disease: untying the Gordian knot
Hajhosseiny, R., Khavandi, K., & Goldsmith, D. J. A. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02954.x · Cited by 208
Maintenance Dialysis throughout the World in Years 1990 and 2010
Thomas, B., Wulf, S., Bikbov, B. T., Perico, N., Cortinovis, M., de Vaccaro, K. C., Flaxman, A. D., Peterson, H. M., Delossantos, A., Haring, D., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101017 · Cited by 204
Chronic kidney disease in adults: assessment and management
Forbes, A., & Gallagher, H. (2020) · Clinical Medicine · doi:10.7861/clinmed.cg.20.2 · Cited by 201
Diabetic Kidney Disease: Challenges, Advances, and Opportunities
Chen, Y., Lee, K., Ni, Z., & He, C. (2020) · Kidney Diseases · doi:10.1159/000506634 · Cited by 206
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
Ricciardi, C. A., & Gnudi, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154890 · Cited by 198
(2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70155-x · Cited by 183
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet, M. H. A., Smits, M. M., Morsink, L. M., & Diamant, M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.272 · Cited by 187
High Burden of Kidney Disease in Youth-Onset Type 2 Diabetes
Dart, A. B., Sellers, E. A. C., Martens, P. J., Rigatto, C., Brownell, M. D., & Dean, H. (2012) · Diabetes Care · doi:10.2337/dc11-2312 · Cited by 181
Bonner, R., Albajrami, O., Hudspeth, J. C., & Upadhyay, A. (2020) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2020.08.004 · Cited by 200
10. Microvascular Complications and Foot Care
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 186
MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets
Kato, M. V., & Natarajan, R. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12758 · Cited by 182
The emerging challenge in diabetes: The “metabolic memory”
Ceriello, A. (2012) · Vascular Pharmacology · doi:10.1016/j.vph.2012.05.005 · Cited by 177
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Fernández‐Fernández, B., Ortíz, A., Gómez‐Guerrero, C., & Egido, J. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.74 · Cited by 172
Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD
Heerspink, H. J. L., & Gansevoort, R. T. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11511114 · Cited by 173
Lachin, J. M., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc20-3097 · Cited by 175
Pozzilli, P., Battelino, T., Danne, T., Hovorka, R., Jarosz-Chobot, P. A., & Renard, É. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2653 · Cited by 167
Management of diabetic nephropathy: Recent progress and future perspective
Ahmad, J. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.02.008 · Cited by 159
Ortíz, A., Abiose, A. K., Bichet, D. G., Cabrera, G. H., Charrow, J., Germain, D. P., Hopkin, R. J., Jovanović, A., Linhart, A., Maruti, S. S., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103486 · Cited by 145
Maahs, D. M., Caramori, M. L., Cherney, D. Z. I., Gałecki, A. T., Gao, C., Jalal, D. I., Perkins, B. A., Pop‐Busui, R., Rossing, P. R., Mauer, M. S., et al. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0381-0 · Cited by 142
Li, S., Huang, P., Yang, A., Tarng, D., Yang, W.-C., Lin, C., Chen, J., Schmid‐Schönbein, G. W., & Lin, S. (2014) · Kidney International · doi:10.1038/ki.2014.67 · Cited by 135
Gubitosi‐Klug, R. (2013) · Diabetes Care · doi:10.2337/dc13-2148 · Cited by 131
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 136
The Genetic Landscape of Renal Complications in Type 1 Diabetes
Sandholm, N., Zuydam, N. V., Ahlqvist, E., Juliusdottir, T., Deshmukh, H., Rayner, N. W., Camillo, B. D., Forsblom, C. M., Fadista, J., Ziemek, D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020231 · Cited by 131
Risk Factors for Kidney Disease in Type 1 Diabetes
Perkins, B. A., Bebu, I., de Boer, I. H., Molitch, M. E., Tamborlane, W. V., Lorenzi, G. M., Herman, W. H., White, N. H., Pop‐Busui, R., Paterson, A. D., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2062 · Cited by 128
Prevention of Microvascular Complications of Diabetes
Crasto, W., Patel, V., Davies, M. J., & Khunti, K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.005 · Cited by 142
Eringa, E. C., Serné, E. H., Meijer, R. I., Schalkwijk, C. G., Houben, A. J. H. M., Stehouwer, C. D. A., Smulders, Y. M., & van Hinsbergh, V. W. M. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9239-7 · Cited by 126
Kirwan, J. P., Courcoulas, A. P., Cummings, D. E., Goldfine, A. B., Kashyap, S. R., Simonson, D. C., Arterburn, D. E., GOURASH, W. F., Vernon, A. H., Jakicic, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2441 · Cited by 133
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 124
Partnering with diabetes educators to improve patient outcomes
Burke, S., Sherr, D., & Lipman, R. D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s40036 · Cited by 135
Nurse Practitioner Care Improves Renal Outcome in Patients with CKD
Peeters, M. J., van Zuilen, A. D., van den Brand, J. A. J. G., Bots, M. L., van Buren, M., ten Dam, M. A. G. J., Kaasjager, K. A. H., Ligtenberg, G., Sijpkens, Y. W. J., Sluiter, H. E., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121222 · Cited by 120
Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study
de Boer, I. H., Gao, X., Cleary, P. A., Bebu, I., Lachin, J. M., Molitch, M. E., Orchard, T., Paterson, A. D., Perkins, B. A., Steffes, M. W., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02870316 · Cited by 114
Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher, H., & Suckling, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12630 · Cited by 112
Bjornstad, P., Cherney, D. Z. I., Snell‐Bergeon, J. K., Pyle, L., Rewers, M., Johnson, R. J., & Maahs, D. M. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv121 · Cited by 111
Glucose targets for preventing diabetic kidney disease and its progression
Ruospo, M., Saglimbene, V. M., Palmer, S. C., De Cosmo, S., Pacilli, A., Lamacchia, O., Cignarelli, M., Fioretto, P., Vecchio, M., Craig, J. C., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010137.pub2 · Cited by 111
Intensive Diabetes Therapy and Ocular Surgery in Type 1 Diabetes
The DCCT/EDIC Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409463 · Cited by 111
Self-citation11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 108
Diabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 109
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 108
Effects of glycaemic management on diabetic kidney disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i5.172 · Cited by 107
Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease
Stanton, R. C. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.10.050 · Cited by 106
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 157
Slinin, Y., Ishani, A., Rector, T., Fitzgerald, P., MacDonald, R., Tacklind, J., Rutks, I., & Wilt, T. J. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.017 · Cited by 99
DNA methylation mediates development of HbA1c-associated complications in type 1 diabetes
Chen, Z., Miao, F., Braffett, B. H., Lachin, J. M., Zhang, L., Wu, X., Roshandel, D., Carless, M. A., Li, X. A., Tompkins, J. D., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0231-8 · Cited by 106
Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria
de Boer, I. H., Afkarian, M., Rue, T. C., Cleary, P. A., Lachin, J. M., Molitch, M. E., Steffes, M. W., Sun, W., & Zinman, B. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013091004 · Cited by 101
Colom, C., Rull, A., Sánchez‐Quesada, J. L., & Pérez, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081798 · Cited by 109
Hill, C. J., Maxwell, A. P., Cardwell, C. R., Freedman, B. I., Tonelli, M. A., Emoto, M., Inaba, M., Hayashino, Y., Fukuhara, S., Okada, T., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.06.020 · Cited by 99
Rosansky, S. J. (2012) · American Journal of Nephrology · doi:10.1159/000339327 · Cited by 92
Cardiac implications of hypoglycaemia in patients with diabetes – a systematic review
Hanefeld, M., Dütting, E. D., & Bramlage, P. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-135 · Cited by 94
Hill, C. J., Cardwell, C. R., Patterson, C. C., Maxwell, A. P., Magee, G. M., Young, R. J., Matthews, B. B., O'Donoghue, D. J., & Fogarty, D. G. (2013) · Diabetic Medicine · doi:10.1111/dme.12312 · Cited by 92
Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes
Helve, J., Sund, R., Arffman, M., Harjutsalo, V., Groop, P., Grönhagen‐Riska, C., & Finne, P. (2017) · Diabetes Care · doi:10.2337/dc17-2364 · Cited by 88
Mini-review: emerging roles of microRNAs in the pathophysiology of renal diseases
Bhatt, K. S., Kato, M. V., & Natarajan, R. D. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00387.2015 · Cited by 87
BP Control and Long-Term Risk of ESRD and Mortality
Ku, E., Gassman, J., Appel, L. J., Smogorzewski, M., Sarnak, M. J., Glidden, D. V., Bakris, G., Gutiérrez, O. M., Hebert, L. A., Ix, J. H., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030326 · Cited by 88
Metadata
- Authors
- The DCCT/EDIC Research Group
- Affiliations
- University of Washington (US)
- Corresponding author
- The DCCT/EDIC Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-22
- Volume
- 365
- Issue
- 25
- Pages
- 2366-2376
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3270008
- OpenAlex
- W2141495158
- Cited by
- 568
- References
- 28
- Citations by year
- 2026: 4 · 2025: 24 · 2024: 20 · 2023: 34 · 2022: 29 · 2021: 32 · 2020: 40 · 2019: 27 · 2018: 35 · 2017: 35 · 2016: 45 · 2015: 54 · 2014: 58 · 2013: 65 · 2012: 61
- FWCI
- 46.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Sanofi
- Northwestern University
- University of Washington
- Novo Nordisk
- Genentech
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087726, RC4DK090766, R01DK088762)
- National Center for Research Resources
- Division of Diabetes, Endocrinology, and Metabolic Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, intensive diabetes therapy, glomerular filtration rate, diabetic nephropathy, end-stage renal disease, glycemic control, HbA1c, albuminuria, chronic kidney disease
- MeSH terms
- Adult, Creatinine, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Follow-Up Studies, Glomerular Filtration Rate, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Kidney Failure, Chronic, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
